Ensign Peak Advisors, Inc Centessa Pharmaceuticals PLC Transaction History
Ensign Peak Advisors, Inc
- $51.2 Billion
- Q1 2025
A detailed history of Ensign Peak Advisors, Inc transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 438,133 shares of CNTA stock, worth $10.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
438,133
Previous 79,000
454.6%
Holding current value
$10.2 Million
Previous $1.32 Million
376.19%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CNTA
# of Institutions
127Shares Held
122MCall Options Held
638KPut Options Held
146K-
Medicxi Ventures Management (Jersey) LTD20MShares$464 Million74.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$231 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$225 Million4.43% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.4MShares$195 Million0.2% of portfolio
-
Janus Henderson Group PLC London, X06.53MShares$152 Million0.04% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $2.19B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...